Literature DB >> 17325215

Importance of collection tube during clinical studies of oseltamivir.

Niklas Lindegardh1, Geraint R Davies, Tran Tinh Hien, Jeremy Farrar, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White.   

Abstract

Ex vivo conversion of the anti-influenza drug oseltamivir to its active metabolite can be inhibited by the esterase inhibitor dichlorvos or by using commercial fluoride-oxalate tubes. Oseltamivir and its active metabolite remain intact in plasma samples during a proposed virus heat inactivation step: incubation at 60 degrees C for 45 min.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325215      PMCID： PMC1855577          DOI： 10.1128/AAC.01534-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.

Authors:  Niklas Lindegardh; Geraint R Davies; Tinh Hien Tran; Jeremy Farrar; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Oseltamivir resistance during treatment of influenza A (H5N1) infection.

Authors:  Menno D de Jong; Tan Thanh Tran; Huu Khanh Truong; Minh Hien Vo; Gavin J D Smith; Vinh Chau Nguyen; Van Cam Bach; Tu Qui Phan; Quang Ha Do; Yi Guan; J S Malik Peiris; Tinh Hien Tran; Jeremy Farrar
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus.

Authors:  L S Martin; J S McDougal; S L Loskoski
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

Review 4.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.

Authors:  C Oo; J Barrett; G Hill; J Mann; A Dorr; R Dutkowski; P Ward
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

Review 7.  Antivirals for influenza in healthy adults: systematic review.

Authors:  T Jefferson; V Demicheli; D Rivetti; M Jones; C Di Pietrantonj; A Rivetti
Journal:  Lancet       Date:  2006-01-28       Impact factor: 79.321

Review 8.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

Authors:  Penelope Ward; Ian Small; James Smith; Pia Suter; Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2005-02       Impact factor: 5.790

9.  Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.

Authors:  B Spire; D Dormont; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

10.  Vaccines and antiviral drugs in pandemic preparedness.

Authors:  Arnold S Monto
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883
View more
  9 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

3.  An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.

Authors:  Sasithon Pukrittayakamee; Podjanee Jittamala; Kasia Stepniewska; Niklas Lindegardh; Sunee Chueasuwanchai; Wattana Leowattana; Aphiradee Phakdeeraj; Sutatip Permpunpanich; Warunee Hanpithakpong; Wirichada Pan-Ngum; Caroline Fukuda; Salwaluk Panapipat; Pratap Singhasivanon; Nicholas J White; Nicholas P J Day
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

4.  Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds.

Authors:  Daniel Blessborn; Karl Sköld; David Zeeberg; Karnrawee Kaewkhao; Olof Sköld; Martin Ahnoff
Journal:  Bioanalysis       Date:  2013-01       Impact factor: 2.681

5.  Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

Authors:  Y Wattanagoon; K Stepniewska; N Lindegårdh; S Pukrittayakamee; U Silachamroon; W Piyaphanee; T Singtoroj; W Hanpithakpong; G Davies; J Tarning; W Pongtavornpinyo; C Fukuda; P Singhasivanon; N P J Day; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

6.  Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

Authors:  Mark Holodniy; Scott R Penzak; Timothy M Straight; Richard T Davey; Kelvin K Lee; Matthew Bidwell Goetz; Dennis W Raisch; Francesca Cunningham; Emil T Lin; Noemi Olivo; Lawrence R Deyton
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

7.  Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.

Authors:  Gero P Hooff; Roland J W Meesters; Jeroen J A van Kampen; Nick A van Huizen; Birgit Koch; Asmar F Y Al Hadithy; Teun van Gelder; Albert D M E Osterhaus; Rob A Gruters; Theo M Luider
Journal:  Anal Bioanal Chem       Date:  2011-05-03       Impact factor: 4.142

8.  Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.

Authors:  Walter R J Taylor; Bui Nghia Thinh; Giang Thuc Anh; Peter Horby; Heiman Wertheim; Niklas Lindegardh; Menno D de Jong; Kasia Stepniewska; Tran Thuy Hanh; Nguyen Duc Hien; Ngo Minh Bien; Ngo Quy Chau; Annette Fox; Nghiem My Ngoc; Martin Crusat; Jeremy J Farrar; Nicholas J White; Nguyen Hong Ha; Trinh Thi Lien; Nguyen Vu Trung; Nicholas Day; Nguyen Gia Binh
Journal:  PLoS One       Date:  2008-10-15       Impact factor: 3.240

9.  Bench to bed evidences for pharmacokinetic and pharmacodynamic interactions involving oseltamivir and chinese medicine.

Authors:  Qi Chang; Siukwan Wo; Karry L K Ngai; Xiaoan Wang; Benny Fok; Teresa M Ngan; Vivian T Wong; Thomas Y K Chan; Vincent H L Lee; Brian Tomlinson; Paul K S Chan; Moses S S Chow; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-09       Impact factor: 2.629
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.